Stock Performance: Rhythm Pharmaceuticals Inc. (RYTM) shares rose 14.24% to $119.69 following positive preliminary results from its Phase 2 trial of setmelanotide for Prader-Willi syndrome (PWS).
Trial Results: In the ongoing 52-week trial, setmelanotide showed potential benefits, with 6 of 8 patients achieving BMI reductions at Month 3 and 3 of 5 patients at Month 6, alongside significant reductions in hyperphagia.
Future Plans: The company plans to advance setmelanotide into a Phase 3 registrational trial for PWS, contingent on the successful completion of the current Phase 2 trial.
Additional Research: Rhythm has initiated a Part D arm in a Phase 1 trial for MC4R agonist RM-718, aiming to enroll up to 20 PWS patients, with the first screening expected in December 2025.
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 140.62 USD with a low forecast of 123.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 140.62 USD with a low forecast of 123.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
H.C. Wainwright
Buy
maintain
$123 -> $125
2026-01-20
New
Reason
H.C. Wainwright
Price Target
$123 -> $125
AI Analysis
2026-01-20
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Rhythm Pharmaceuticals to $125 from $123 and keeps a Buy rating on the shares. The company's preliminary Q4 revenue beat estimates, the analyst tells investors in a research note.
Wells Fargo
Derek Archila
Overweight
maintain
$129 -> $145
2026-01-20
New
Reason
Wells Fargo
Derek Archila
Price Target
$129 -> $145
2026-01-20
New
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila raised the firm's price target on Rhythm Pharmaceuticals to $145 from $129 and keeps an Overweight rating on the shares. The firm says IMCIVREE's Q4 revenue beat was a positive surprise. Its IMCIVREE revenue estimates largely remain unchanged for FY26 though it pushes its modest Q1 hypothalamic obesity sales due to the PDUFA extension. However, based on Wells' management dinner, it is now incorporating Prader-Willi syndrome into its model at a 35% probability of success.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RYTM
Unlock Now
H.C. Wainwright
Raghuram Selvaraju
Buy
upgrade
$110 -> $123
2025-12-22
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$110 -> $123
2025-12-22
upgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Rhythm Pharmaceuticals to $123 from $110 and keeps a Buy rating on the shares. The firm says the company's Prader-Willi syndrome proof-of-concept data demonstrates setmelanotide has a therapeutic impact. It nstituted forward sales forecasts for setmelanotide in PWS in the U.S. only, with a 60% probability of regulatory approval.
Guggenheim
Seamus Fernandez
Buy
maintain
$120 -> $140
2025-12-17
Reason
Guggenheim
Seamus Fernandez
Price Target
$120 -> $140
2025-12-17
maintain
Buy
Reason
Guggenheim analyst Seamus Fernandez raised the firm's price target on Rhythm Pharmaceuticals to $140 from $120 and keeps a Buy rating on the shares. Last week's preliminary Prader-Willi syndrome data for setmelanotide suggests "promising" monotherapy activity in this indication, the analyst tells investors.
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
